PRKAA1 and Other metabolic disease: In conclusions, the present study demonstrates that Rho-kinase inhibition ameliorates metabolic disorders through activation of the LKB1/AMPK pathway in mice, suggesting that Rho-kinase could be a novel therapeutic target of metabolic disorders.